Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (12376)	12/3/1999 10:20:00 AM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

You stated>>>>>>>Did IPIC give the drug for peanuts? seems that the market thinks the opposite.<<<<<<< That was yesterday........see what the market thinks of IPIC and Biogen TODAY!<g> This is from Bloomberg talking about Biogen's anti Psoriasis drug>>>>>>>>>Should the drug make it to market, physicians are likely to scrutinize the results of Amevive's clinical trials because the drug faces competition from at least two other experimental drugs now in final stages of testing -- Immunex Corp.'s Enbrel, which is already approved for rheumatoid arthritis, and an experimental compound being developed jointly by Genentech Inc. and Xoma Ltd.<<<<<<<< Now as I was stating my opinion on Xoma having the gold standard. Hmmmmmm. Cacaito, I know you are bitter about Xoma. Are you having any luck in any other Biotechs?